IUCT Oncopôle

Running trials

• Not yet recruiting

  Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy

  NCT07814001· Phase 2· Source

• Not yet recruiting

  Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia

  NCT07386392· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  NCT06782373· Phase 2· Source

• Recruiting

  Association Between the SPHERTEST in Vitro Test and Response to Checkpoint Inhibitor Treatments in Patients With Advanced or Metastatic Urothelial Carcinoma

  NCT06738797· Source

• Recruiting

  Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

  NCT06271057· Phase 2· Source

• Recruiting

  Study of REM-422 in Patients With AML or Higher Risk MDS

  NCT06297941· Phase 1· Source

• Active, not recruiting

  Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

  NCT05768711· Phase 2· Source

• Recruiting

  Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy

  NCT05944913· Source

• Active, not recruiting

  Prevention of Alopecia in Patients With Localised Breast Cancer

  NCT06011525· Source

• Recruiting

  Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

  NCT05246345· Source

• Active, not recruiting

  Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

  NCT04802590· Phase 2· Source

• Recruiting

  Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

  NCT04698785· Phase 2· Source

• Active, not recruiting

  Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

  NCT03915678· Phase 2· Source

• Active, not recruiting

  A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

  NCT03223961· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

  NCT03049189· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Sarcoma2 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Follicular lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

  NCT05091424· Phase 1· Source

• Completed

  Targeting ATR in Soft-tissue Sarcomas

  NCT04807816· Phase 2· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Source

• Completed

  Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

  NCT04703686· Phase 2· Source

• Recruiting

  A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  NCT04710576· Phase 2· Source

• Completed

  Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

  NCT03249870· Phase 2· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Source

• Completed

  French Registry of First-line Treatment of Acute Promyelocytic Leukemia

  NCT02938858· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Source